Prolonged IL-1beta exposure alters neurotransmitter and electrically induced Ca(2+) responses in the myenteric plexus.
BACKGROUND Infection and inflammatory diseases of the gut results in profound changes of intestinal motor function. Acute administration of the pro-inflammatory cytokine interleukin-1beta (IL-1beta) was shown to have excitatory and neuromodulatory roles in the myenteric plexus. Here we aimed to study the effect of prolonged IL-1beta incubation on the response of myenteric neurones to different stimuli. METHODS Longitudinal muscle myenteric plexus preparations (LMMP's) of the guinea pig jejunum were incubated for 24 h in medium with or without IL-1beta. After loading with Fluo-4, calcium imaging was used to visualize activation of neurones. The response to application of serotonin (5-HT), substance P (SP) and ATP or to electrical fibre tract stimulation (eFTS) was tested. Expression of nNOS, HuD, calbindin and calretinin was compared by immunohistochemistry. KEY RESULTS IL-1beta concentration-dependently influenced the neuronal responsiveness and duration of the [Ca(2+)](i) rises to 5-HT and ATP, while it also affected the Ca(2+)-transient amplitudes induced by 5-HT, ATP and SP. Ca(2+)-transients in response to eFTS were observed in significantly more neurones per ganglion after IL-1beta (10(-10) and 10(-11) mol L(-1)). Peak [Ca(2+)](i) rise after eFTS was concentration-dependently decreased by IL-1beta. The duration of the [Ca(2+)](i) rise after eFTS was prolonged after IL-1beta 10(-12) mol L(-1). IL-1beta (10(-9) mol L(-1)) incubation did not affect the number of nNOS, calretinin and calbindin expressing neurones, nor did it induce neuronal loss (HuD). CONCLUSIONS & INFERENCES In this study, IL-1beta differentially modulates the neuronal response to eFTS and neurotransmitter application in the myenteric plexus of guinea pigs. This cytokine could be implicated in the motility disturbances observed during gastrointestinal inflammation.
Kindt
S
S
Center for Gastroenterological Research, K. U. Leuven, Leuven, Belgium.
Vanden Berghe
P
P
Boesmans
W
W
Roosen
L
L
Tack
J
J
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000255:Adenosine Triphosphate / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D064032:Calbindin 2; D064026:Calbindins; D002118:Calcium / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D051959:ELAV Proteins / Q000378:metabolism; D004558:Electric Stimulation; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects / Q000502:physiology; D005260:Female; D006168:Guinea Pigs; D007091:Image Processing, Computer-Assisted; D007150:Immunohistochemistry; D053583:Interleukin-1beta / Q000494:pharmacology*; D007583:Jejunum / Q000187:drug effects* / Q000502:physiology; D008297:Male; D018613:Microscopy, Confocal; D009197:Myenteric Plexus / Q000187:drug effects* / Q000502:physiology*; D009474:Neurons / Q000187:drug effects* / Q000502:physiology; D052248:Nitric Oxide Synthase Type I / Q000378:metabolism; D064030:S100 Calcium Binding Protein G / Q000378:metabolism; D012701:Serotonin / Q000494:pharmacology; D013373:Substance P / Q000494:pharmacology; D009435:Synaptic Transmission / Q000187:drug effects
D064032:Calbindin 2; D064026:Calbindins; D051959:ELAV Proteins; D053583:Interleukin-1beta; D064030:S100 Calcium Binding Protein G; D012701:Serotonin; D013373:Substance P; D000255:Adenosine Triphosphate; D052248:Nitric Oxide Synthase Type I; D002118:Calcium